Not really in pipeline, FRX has Namenda XR (approved)to be launching in late 2012 or early 2013 for AZ. But that is for switching Namenda IR (patent expiring in 2015).
In pipeline, they have a POCD product with PDUFA in April/12, and a constipation product with PDUFA in June/12. A few products in Phase III. Their potential is hard to predict based on current health-insurance environment, even though the company has a good record in selling drugs IN HISTORY (yesterday's story). -- How many big pharmas have cut their sales force into the bone?